Michigan State University
Meet the Teams
How can we help?
Tech Transfer & Commercialization
Startups & Entrepreneurship
Browse this Section...
Search Results - kathy+steece-collier
Nurr1 as a Genetic Target for Treating Levodopa-induced Dyskinesias (LIDs) in Parkinson's Disease
Executive SummaryPatients afflicted with Parkinson’s disease often develop severely debilitating movement disorders as side effects from currently available treatment options. Researchers at MSU propose to use a new gene therapy approach that will both reduce these side effects and prolong the effectiveness of treatment by targeted gene silencing.Description...
Genetic Targets and Gene Therapies for Treating Levodopa-induced Dyskinesias for Parkinsonisms
IntroductionThe Parkinson’s Disease Foundation estimates that there are 1.0 to 1.5 million people suffering from Parkinson’s disease (PD) in the United States alone. Those suffering from PD are afflicted with tremors in the limbs and face, rigidity and stiffness of the limbs and trunk, slowed movement, postural instability, and impaired...
Back To Top